Tremor: Clinical Trials

14 trials for Tremor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed. 14 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 214Completed 14
Phase 12Completed 2

Follow Tremor: new trials by email Literature Review of Tremor trials Research Report on Tremor

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease
Placebo, Suvecaltamide - Parkinson Disease, Tremor
Phase 2CompletedJazz Pharmaceuticals1692022-12-012026-01-15
A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)
JZP385, Placebo - Essential Tremor
Phase 2CompletedJazz Pharmaceuticals4202021-12-062025-07-24
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
Cannabidiol, Placebo - Parkinson Disease
Phase 2CompletedUniversity of Colorado, Denver742018-09-052024-07-23
Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease
Onabotulinumtoxin A Injection, Placebo - Parkinson Disease
Phase 2CompletedUniversity of North Carolina, Chapel Hill162018-03-222020-08-17
A Study to Evaluate SAGE-217 in Participants With Essential Tremor
SAGE-217, Placebo - Essential Tremor
Phase 2CompletedBiogen342017-03-242023-11-28
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
cannabidiol - Parkinson's Disease
Phase 2CompletedUniversity of Colorado, Denver132016-10-012019-02-19
Effects of Octanoic Acid for Treatment of Essential Voice Tremor
Octanoic acid, Inactive capsule - Essential Voice Tremor, Vocal Tremor
Phase 1 / Phase 2CompletedSyracuse University172013-07-012018-08-20
Randomised Crossover Trial of DBS of Differential PSA Regions in Parkinson's Disease and Tremor
Up to 3 mA, 60 us, 130 Hz deep brain stimulation, Empirical unblinded deep brain stimulation programming - Parkinson's Disease, Tremor
Phase 2CompletedThe University of Western Australia392012-08-012021-05-18
Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach
incobotulinumtoxinA, Saline - Parkinson, Tremor
Phase 2CompletedYale University332012-08-012016-03-14
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Sodium oxybate - Spasmodic Dysphonia, Voice Tremor
Phase 2CompletedKristina Simonyan532012-07-012017-11-22
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
ST101, Placebo - Essential Tremor
Phase 2CompletedSonexa Therapeutics, Inc.252011-04-012012-01-06
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
Carisbamate, Placebo - Essential Tremor, Movement Disorders
Phase 2CompletedSK Life Science, Inc.622007-08-012013-01-24
Efficacy of Levetiracetam in Essential Tremor
levetiracetam, placebo - Essential Tremor
Phase 1 / Phase 2CompletedSouthern California Institute for Research and Education102005-01-012009-04-17
Effect of Alcohol on Tremors
Alcohol - Tremor
Phase 2CompletedNational Institute of Neurological Disorders and Stroke (NINDS)231999-01-012008-03-04

Narrower conditions

Essential Tremor (7)  ·  Parkinson Disease (5)  ·  Movement Disorders (3)  ·  Anxiety Disorders (2)  ·  Dyskinesias (2)  ·  Dysphonia (2)  ·  Marijuana Abuse (2)  ·  Psychotic Disorders (2)  ·  Dermatitis, Seborrheic (1)  ·  Dystonia (1)  ·  Voice Disorders (1)

Broader conditions

Nervous System Diseases (14)  ·  Neurologic Manifestations (14)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (14)  ·  Dyskinesias (12)  ·  Central Nervous System Diseases (11)  ·  Movement Disorders (8)  ·  Basal Ganglia Diseases (5)  ·  Brain Diseases (5)  ·  Neurodegenerative Diseases (5)  ·  Parkinsonian Disorders (5)  ·  Synucleinopathies (5)  ·  Chemically-Induced Disorders (2)  ·  Laryngeal Diseases (2)  ·  Mental Disorders (2)

Interventions

Cannabidiol (2)  ·  Botulinum Toxins, Type A (1)  ·  Ethanol (1)  ·  Levetiracetam (1)  ·  S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Sodium Oxybate (1)  ·  incobotulinumtoxinA (1)  ·  octanoic acid (1)  ·  zuranolone (1)

Sponsors

Jazz Pharmaceuticals (2)  ·  University of Colorado, Denver (2)  ·  Biogen (1)  ·  Kristina Simonyan (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  SK Life Science, Inc. (1)  ·  Sonexa Therapeutics, Inc. (1)  ·  Southern California Institute for Research and Education (1)  ·  Syracuse University (1)  ·  The University of Western Australia (1)  ·  University of North Carolina, Chapel Hill (1)  ·  Yale University (1)

Countries

United States (12)  ·  Germany (2)  ·  Poland (2)  ·  Spain (2)  ·  Australia (1)

Top investigators

Bahman Jabbari, MD (1)  ·  Christopher Lind, MBChB, FRACS (1)  ·  Daniel A Roque, MD (1)  ·  Kristina Simonyan, MD, PhD (1)  ·  Maureen A Leehey, M.D. (1)  ·  Maureen Leehey (1)  ·  Soren Y Lowell, PhD (1)  ·  Steven S Schreiber, MD (1)

Results publications

PMID 14718713, PMID 15210907, PMID 20201005, PMID 21594724, PMID 22454323, PMID 23408867, PMID 25929664, PMID 27808415, PMID 28789780, PMID 30382161, PMID 37448353, PMID 38466972

NIH funding

R01DC012545 (1), R03DC012429 (1)